ID: ALA5202474

Max Phase: Preclinical

Molecular Formula: C27H29F2N5O4

Molecular Weight: 525.56

Associated Items:

Representations

Canonical SMILES:  O=C(O)CC1CCC2(CC1)CCC(c1ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cn1)CC2

Standard InChI:  InChI=1S/C27H29F2N5O4/c28-20-3-1-18(14-21(20)29)32-26-34-33-25(38-26)24(37)31-19-2-4-22(30-15-19)17-7-11-27(12-8-17)9-5-16(6-10-27)13-23(35)36/h1-4,14-17H,5-13H2,(H,31,37)(H,32,34)(H,35,36)

Standard InChI Key:  QKTPNXWLDUSRAW-UHFFFAOYSA-N

Associated Targets(Human)

Diacylglycerol O-acyltransferase 1 1719 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Diacylglycerol O-acyltransferase 2 347 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 703 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Acetyl-CoA acetyltransferase, mitochondrial 21 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 525.56Molecular Weight (Monoisotopic): 525.2188AlogP: 6.05#Rotatable Bonds: 7
Polar Surface Area: 130.24Molecular Species: ACIDHBA: 7HBD: 3
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.96CX Basic pKa: 4.34CX LogP: 4.17CX LogD: 1.49
Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.34Np Likeness Score: -1.05

References

1. Koul S, Kurhade S, Bhosale S, Naik K, Salunkhe V, Ravula S, Punde P, Velayutham R, Tiwari A, Ahl D, Malkapuram S, Mudagala V, Raje A, Umrani D, Tambe S, Patil P, Singh U, Bhuniya D, Hariharan N, Mookhtiar K..  (2022)  Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation.,  62  [PMID:35189320] [10.1016/j.bmcl.2022.128632]
2. Koul S, Kurhade S, Bhosale S, Naik K, Salunkhe V, Ravula S, Punde P, Velayutham R, Tiwari A, Ahl D, Malkapuram S, Mudagala V, Raje A, Umrani D, Tambe S, Patil P, Singh U, Bhuniya D, Hariharan N, Mookhtiar K..  (2022)  Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation.,  62  [PMID:35189320] [10.1016/j.bmcl.2022.128632]
3. Koul S, Kurhade S, Bhosale S, Naik K, Salunkhe V, Ravula S, Punde P, Velayutham R, Tiwari A, Ahl D, Malkapuram S, Mudagala V, Raje A, Umrani D, Tambe S, Patil P, Singh U, Bhuniya D, Hariharan N, Mookhtiar K..  (2022)  Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation.,  62  [PMID:35189320] [10.1016/j.bmcl.2022.128632]

Source